Orladeyo (berotralstat) is FDA indicated to treat Hereditary Angioedema
… FDA Approves Orladeyo (berotralstat) for Hereditary Angioedema patients …

Orladeyo (berotralstat) by BioCryst Pharmaceuticals Earns FDA Approval

A new cardiovascular agent treats Hereditary Angioedema (HAE)

Orladeyo’s oral formulation is a competitive advantage

Orladeyo’s oral formulation is an added element to its market access strategy

BioCryst is a compact, R&D-focused biopharmaceutical enterprise

The FDA has been on a roll with evaluating advanced new therapies for rare diseases and improving their availability to patients and medical professionals

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences https://www.BareSkyMarketing.com/